Document:

EX-10.29

 Exhibit 10.29 

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant
treats as private or confidential. 
 AMENDMENT # 5 TO EXCLUSIVE LICENSE AGREEMENT 

BETWEEN IONQ, INC. DUKE UNIVERSITY AND UNIVERSITIY OF MARYLAND 

This Amendment #5 to the Exclusive License Agreement entered into by and between Duke University, a nonprofit educational and research
institution organized under the laws of North Carolina (“DUKE”) and IonQ, Inc. (“Licensee”) is effective as of the date of last signature below. 

Background: UMD and Licensee executed an Exclusive License Agreement dated effective July 19, 2016 and amended September 22, 2017, October 4,
2018, and April 27, 2021 (collectively “Exclusive License Agreement”). In connection with the Exclusive License Agreement, DUKE and Licensee executed an Exclusive Option Agreement, effective July 15, 2016, which was amended on
December 18, 2020 (“Option Agreement”). Under the terms and conditions of the Option Agreement, DUKE granted Licensee, and Licensee accepted, an exclusive option during the Option Period (as defined in the Option
Agreement) to obtain a worldwide exclusive license, with the right to sublicense, under the Exclusive License Agreement to DUKE’s rights in Option IP (the “Option”). DUKE has disclosed certain Option IP to Licensee and Licensee elects
to exercise its Option to license such Option IP by executing this Amendment #5 to the Exclusive License Agreement. To that end, DUKE and Licensee hereby agree that the Exclusive License Agreement is amended as follows: 

1.    The definition of Licensed Inventions in Section 1.09 is modified to add at the end of the definition: “and [***] and the
related detailed descriptions.” 
 2.    Appendix A to the Exclusive License Agreement shall be replaced with the attached Appendix
A. 
 3.    All other terms and conditions of the Exclusive License Agreement shall apply to the Option Intellectual Property (as that
term is defined in the Option Agreement) optioned by Licensee pursuant to the Option Agreement and identified in this Amendment as if such intellectual property had been included in the scope of the Exclusive License Agreement as of its Effective
Date. 
 4.    Except for the amendments set forth herein, all other terms and conditions of the Exclusive License Agreement remain in
full force and effect. 
 ACCEPTED AND AGREED TO 
  

									
	DUKE UNIVERSITY	 		 	IONQ, INC.
					
	BY	 	 /s/ Eric F. Wagner, Ph.D., J.D.
	 		 	BY	 	 s/ Francisco Castro

	NAME: Eric F. Wagner, Ph.D., J.D.	 		 	NAME: Francisco Castro, Ph.D.
	Title: Director – Legal Affairs	 		 	Title: Chief IP Counsel
	Office of Translation & Commercialization	 		 		 	
			
	DATE: 9/10/2021	 		 	DATE: 9/10/2021

 APPENDIX A – Duke Patents and IP 

[***] 

  
 Page 2 of 2EX-10.30

 Exhibit 10.30 

Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant
treats as private or confidential. 
 AMENDMENT #5 TO EXCLUSIVE LICENSE AGREEMENT 

BETWEEN IONQ, INC. AND UNIVERSITY OF MARYLAND 

This Amendment #5 to the Exclusive License Agreement (Amendment) entered into by and between the University of Maryland (UMD) and ionQ, Inc.
(Licensee) is effective as of the date of last signature below. 
 Background: UMD and Licensee executed an Exclusive License Agreement dated effective
July 19, 2016 (Exclusive License Agreement). In connection with the Exclusive License Agreement, UMD and Licensee executed an Exclusive Option Agreement, effective July 19, 2016 (Option Agreement). Under the terms and conditions of the
Option Agreement, UMD granted Licensee and Licensee accepted an exclusive option during the Option Period to obtain a worldwide exclusive license, with the right to sublicense, under the Exclusive License Agreement to UMD’s rights in Option IP
(the “Option”). UMD has disclosed certain Option IP to Licensee and Licensee elects to exercise its Option to license such Option IP by executing this Amendment #5 to the Exclusive License Agreement. To that end, UMD and Licensee hereby
agree that the Exclusive License Agreement is amended as follows: 
  

	1.	 The definition of Licensed Inventions in Section 1.11 is modified to add at the end of the definition:
“and [***], and the related detailed descriptions.” 

  

	2.	 Appendix A to the Exclusive License Agreement is modified by adding the following to the list of Patent Rights:
[***]. 

  

	3.	 All other terms and conditions of the Exclusive License Agreement shall apply to the Option Intellectual
Property (as that term is defined in the Option Agreement) optioned by Licensee pursuant to the Option Agreement and identified in this Amendment as if such intellectual property had been included in the scope of the Exclusive License Agreement as
of its Effective Date. 

  

	4.	 Except for the amendments set forth herein, all other terms and conditions of the Exclusive License Agreement
remain in full force and effect. 

 ACCEPTED AND AGREED TO: 
  

					
	UNIVERSITY OF MARYLAND	 		 	IONQ, INC.
			
	 BY /s/ Kenneth Porter
	 		 	 BY /s/ Francisco Castro

	Kenneth Porter, Director	 		 	Francisco Castro, Ph.D., Chief IP Counsel
			
	DATE: 9/24/2021	 		 	DATE: 9/24/2021EX-10.34

 Exhibit 10.34 

IONQ, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY 
 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or
consultant to IonQ, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this
Non-Employee Director Compensation Policy for his or her Board service following the closing of the transactions contemplated by the Agreement and Plan of Merger, dated March 7, 2021, by and among IonQ
Quantum, Inc., a Delaware corporation (formerly known as IonQ, Inc.), dMY Technology Group, Inc. III, a Delaware corporation, and IonQ Trap Acquisition, Inc., a Delaware corporation and a direct, wholly owned subsidiary of dMY (the
“Effective Date”). This policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or a designated committee of the Board. Unless otherwise defined herein, capitalized
terms used in this policy will have the meaning given to such terms in the Company’s 2021 Equity Incentive Plan or any successor equity incentive plan (the “Plan”). 

 

	I.	 Annual Cash Compensation 

Each Eligible Director will be entitled to receive the following annual cash retainers for service on the Board: 

Annual Board Service Retainer: 
  

	 	•	 	 All Eligible Directors: $30,000 

 

	 	•	 	 Lead Director (additional retainer): $15,000 

 

	 	•	 	 Non-Executive Chair (additional retainer): $20,000

 Annual Committee Chair Service Retainer (in lieu of Annual Committee Member Service Retainer): 

 

	 	•	 	 Chair of the Audit Committee: $20,000 

 

	 	•	 	 Chair of the Compensation Committee: $12,000 

 

	 	•	 	 Chair of the Nominating and Corporate Governance Committee: $8,000 

Annual Committee Member Service Retainer: 
  

	 	•	 	 Member of the Audit Committee: $8,000 

 

	 	•	 	 Member of the Compensation Committee: $6,000 

 

	 	•	 	 Member of the Nominating and Corporate Governance Committee: $4,000 

The annual cash retainers set forth above will be payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter (each
such date, a “Retainer Accrual Date”) in which the service occurred, prorated for any partial quarter of service (based on the number of days served in the applicable position divided by the total number of days in the
quarter). All annual cash fees are vested upon payment. 
  

	II.	 Election to Receive Shares of Common Stock in Lieu of Cash Retainer 

 

	 	A.	 Retainer Grant. Each Eligible Director may elect to convert all of his or her cash compensation under
Section I for the first calendar quarter that commences after the Effective Date and any subsequent calendar quarter into an RSU Award (each, a “Retainer Grant”) in accordance with this Section II(A) (such election, a
“Retainer Grant Election”). If an Eligible Director timely makes a Retainer Grant Election pursuant to Section II(B) below, on the first business day following the applicable Retainer Accrual Date to which the Retainer Grant
Election applies, and without any further action by the Board or designated committee of the Board, such Eligible Director automatically will be 

	 	
granted an RSU Award covering a number of shares of common stock equal to (a) the aggregate amount of cash compensation otherwise payable to such Eligible Director on the Retainer Accrual
Date to which the Retainer Grant Election applies divided by (b) the closing sales price per share of the common stock on the applicable Retainer Accrual Date (or, if such date is not a business day, on the first business day thereafter),
rounded down to the nearest whole share. Each Retainer Grant will be fully vested on the applicable grant date. 

  

	 	B.	 Election Mechanics. Each Retainer Grant Election must be submitted to the Company’s Chief Financial
Officer (or such other individual as the Company designates) in writing at least 20 business days in advance of the applicable Retainer Accrual Date, and subject to any other conditions specified by the Board or designated committee of the Board. An
Eligible Director may only make a Retainer Grant Election during a period in which the Company is not in a quarterly or special blackout period and the Eligible Director is not aware of any material non-public
information. Once a Retainer Grant Election is properly submitted, it will be in effect for the next Retainer Accrual Date and will remain in effect for successive Retainer Accrual Dates unless and until the Eligible Director revokes it in
accordance with Section II(C) below. An Eligible Director who fails to make a timely Retainer Grant Election will not receive a Retainer Grant and instead will receive the cash compensation set forth under Section I. 

 

	 	C.	 Revocation Mechanics. The revocation of any Retainer Grant Election must be submitted to the
Company’s Chief Financial Officer (or such other individual as the Company designates) in writing at least 20 business days in advance of the applicable Retainer Accrual Date, and subject to any other conditions specified by the Board or
designated committee of the Board. An Eligible Director may only revoke a Retainer Grant Election during a period in which the Company is not in a quarterly or special blackout period and the Eligible Director is not aware of any material non-public information. Once the revocation of the Retainer Grant Election is properly submitted, it will be in effect for the next Retainer Accrual Date and will remain in effect for successive Retainer Accrual
Dates unless and until the Eligible Director makes a new Retainer Grant Election in accordance with Section (II)(B). 

  

	III.	 Equity Compensation 

All grants of equity awards to Eligible Directors pursuant to this policy will be automatic and nondiscretionary (without the need for any additional corporate
action by the Board or designated committee of the Board) and will be made in accordance with the following provisions: 
  

	 	A.	 Initial Grant: For each Eligible Director who is first elected or appointed to the Board following the
Effective Date, on the date of such Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be granted a restricted
stock unit award (“RSU Award”) and an option to purchase shares of common stock (“Stock Option Award”) with an aggregate Fair Market Value as of the grant date equal to $400,000 (the
“Initial Grant”), with such value split equally between the RSU Award and Stock Option Award. The Initial Grant will vest over a three-year period, with one-third of the Initial Grant
vesting on each anniversary of the grant date, such that the Initial Grant is fully vested on the third anniversary of the date of grant, subject to the Eligible Director’s continued service as a member of the Board through each such vesting
date. 

  
 2 

	 	B.	 Annual Grant: On the first business day following each annual stockholder meeting of the Company (each,
an “Annual Meeting”) held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board following such Annual Meeting (excluding any
Eligible Director who is first appointed or elected by the Board at the Annual Meeting) will be granted an RSU Award and an Stock Option Award with an aggregate Fair Market Value as of the grant date equal to $200,000 (the “Annual
Grant”), with such value split equally between the RSU Award and Stock Option Award. The Annual Grant will vest in full on the earlier of (i) the date of the following year’s Annual Meeting (or the date immediately prior to
the next Annual Meeting if the Non-Employee Director’s service as a director ends at such Annual Meeting due to the director’s failure to be re-elected or the
director not standing for re-election), or (ii) the one-year anniversary measured from the date of grant, subject in all cases to the Eligible Director’s
continued service as a member of the Board through such vesting date. With respect to an Eligible Director who, following the Effective Date, was first elected or appointed to the Board on a date other than the date of the Annual Meeting, upon the
first Annual Meeting following such Eligible Director’s first joining the Board, such Eligible Director’s first Annual Grant will be pro-rated to reflect the time between such Eligible
Director’s election or appointment date and the date of such first Annual Meeting. 

  

	 	C.	 Calculation of RSU Awards and Option Awards. The number of shares subject to each RSU Award granted
pursuant to the Initial Grant or Annual Grant shall be the total RSU Award value, divided by the average closing market price of our common stock over the 22 trading days ending the business day before the date of grant. The number of shares subject
to each Option Award granted pursuant to the Initial Grant or Annual Grant shall be determined using a Black-Scholes option pricing model based on the average closing market price of our common stock over the 22 trading days ending the business day
before the date of grant. 

  

	 	D.	 Settlement of RSUs: The common stock to be issued upon settlement of vested RSUs under Initial Grant and
Annual Grant will be delivered on the applicable vesting date, or as soon as practicable thereafter, subject to the terms and conditions of the applicable form of RSU grant notice and agreement approved by the Board, provided, that such
common stock shall be delivered no later than the date that is the 15th day of the third calendar month of the year following the year in which such shares are no longer subject to a
“substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d). 

  

	 	E.	 Acceleration: Notwithstanding the foregoing vesting schedules and subject to the Eligible
Director’s Continuous Service (as defined in the Plan), through the closing of a Change in Control (as defined in the Plan), all outstanding and unvested equity awards held by such Eligible Director, whether granted under this policy or
otherwise, will vest in full immediately prior to, but conditioned upon, the closing of a Change in Control. 

  

	 	F.	 Additional Provisions: All Option Awards granted under this policy will be nonstatutory stock options,
with an exercise price per share equal to 100% of the Fair Market Value of the underlying common stock on the date of grant, and a term of 10 years from the date of grant (subject to earlier termination in connection with a termination of Continuous
Service or a Corporate Transaction as provided in the Plan). All provisions of the Plan not inconsistent with this policy will apply to awards granted to Eligible Directors. Eligible Directors will be required to execute an restricted stock unit and
option award agreement in a form satisfactory to the Company prior to receipt of an Initial Grant or Annual Grant. 

  
 3 

	IV.	 Non-Employee Director Compensation Limit 

Notwithstanding the foregoing, the aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Nonemployee Director
(as defined in the Plan) shall in no event exceed the limits set forth in Section 3(d) of the Plan. 
  

	V.	 Ability to Decline Compensation 

An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity
awards are to be granted, as the case may be. 
  

	VI.	 Expenses 

The Company will reimburse Eligible Directors for ordinary, necessary and reasonable
out-of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings; provided, that
the Eligible Director timely submit to the Company appropriate documentation substantiating such expenses in accordance with the Company’s travel and expense policy, as in effect from time to time. 

Approved: December 14, 2021 

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]